Effectiveness of smoking cessation pharmacotherapies during pregnancy: A multi‐national population‐based study
Addiction · 2026
DOI: 10.1111/add.70290 ↗Kurz gefasst
Fachartikel in der Zeitschrift Addiction, 2026. Verfasst von Annelies L Robijn und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Drug and Alcohol Research Centre, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Smoking Cessation, Tobacco Use Cessation Devices, Smoking Cessation Agents, Pregnancy Complications. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: UNSW Research Infrastructure Scheme, National Health and Medical Research Council, Department of Health and Aged Care, Australian Government.
Abstract (Originalsprache)
Aims
As clinical trial evidence on the effectiveness of smoking cessation pharmacotherapies during pregnancy is inconclusive, we conducted a large cohort study examining their effectiveness and comparative effectiveness during pregnancy.
Design
Population‐based cohort study. We used propensity score matching and conditional Poisson regression to compare pharmacotherapy‐exposed with unexposed pregnancies, and to compare varenicline‐exposed with nicotine replacement therapy (NRT) ‐exposed pregnancies.
Setting
Birth records (2005–2020) from New South Wales (NSW) Australia, New Zealand (NZ) and Norway/Sweden linked to pharmacotherapy dispensing records. Participants/cases Women with a birth record indicating smoking in early pregnancy [during first 20 weeks' gestation (NSW), at lead maternity registration (NZ) or during the first trimester (Norway/Sweden)]. Participants were dispensed prescription NRT, varenicline or bupropion in the first 18 weeks of gestation (NSW, Norway/Sweden) or between the first antenatal visit and childbirth (NZ).
Measurements
We defined smoking cessation as not smoking after gestational week 20 (NSW), at gestational week 32–36 (Norway/Sweden) and at two weeks postpartum (NZ), identified via self‐report and documented in the birth record.
Findings
Our NRT analyses included 623, 7074 and 70 exposed and 6026, 68 161 and 700 propensity‐score‐matched unexposed pregnancies from NSW, NZ and Norway/Sweden, respectively. The associations between NRT and smoking cessation were mixed but tended toward reduced cessation compared with no pharmacotherapy. In NSW, NRT was associated with a reduction in cessation [relative risk (RR) = 0.68, 95% confidence interval (CI) = 0.48–0.97], while in NZ, the effect was smaller (RR = 0.93, 95% CI = 0.89–0.98) but inconclusive in Norway/Sweden (RR = 0.91, 95% CI = 0.61–1.35). Smoking cessation was also equally or less common among varenicline‐exposed pregnancies (NSW: 308 exposed vs 3077 matched unexposed, RR = 0.89, 95% CI = 0.72–1.09, Norway/Sweden: 196 exposed vs 1960 matched unexposed, RR = 0.49, 95% CI = 0.34–0.70). Our comparison of varenicline‐exposed with NRT‐exposed pregnancies indicated increased smoking cessation among varenicline‐exposed pregnancies (NSW: 108 vs 154 exposed, RR = 1.91, 95% CI = 1.10–3.22). There were too few bupropion‐exposed pregnancies to support interpretation.
Conclusions
Varenicline appears to be more effective at smoking cessation than nicotine replacement therapy during pregnancy. The uncertainty about the real‐world effectiveness of nicotine replacement therapy and bupropion remains as this study's analyses were impacted by non‐adherence and biased by unmeasured confounding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Drug and Alcohol Research Centre, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, New South Wales, Australia.
- Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago - Ōtākou Whakaihu Waka, Dunedin, New Zealand.
- Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
- Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- New Zealand Pharmacovigilance Centre, Division of Health Sciences, University of Otago - Ōtākou Whakaihu Waka, Dunedin, New Zealand.
- Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, New South Wales, Australia.
ORCID-Profile: Alys Havard
Förderung
- UNSW Research Infrastructure Scheme
- National Health and Medical Research Council
- Department of Health and Aged Care, Australian Government
- UNSW Scientia Program
- NHMRC Medicines Intelligence Centre of Research Excellence
- Research Council of Norway
- Research Council of Norway through its Centres of Excellence
- Norges Forskningsråd
Zitieren
APA
Robijn, A. L., Donald, S., Cohen, J. M., Tran, D. T., Cesta, C. E., Furu, K., Parkin, L., Pearson, S. A., Reutfors, J., Zoega, H., Zwar, N., & Havard, A. (2026). Effectiveness of smoking cessation pharmacotherapies during pregnancy: A multi‐national population‐based study. Addiction. https://doi.org/10.1111/add.70290
Vancouver
Robijn AL, Donald S, Cohen JM, Tran DT, Cesta CE, Furu K, et al. Effectiveness of smoking cessation pharmacotherapies during pregnancy: A multi‐national population‐based study. Addiction. 2026. doi:10.1111/add.70290
BibTeX
@article{Robijn2026,
author = {Robijn, Annelies L and Donald, Sarah and Cohen, Jacqueline M and Tran, Duong T and Cesta, Carolyn E and Furu, Kari and Parkin, Lianne and Pearson, Sallie-Anne and Reutfors, Johan and Zoega, Helga and Zwar, Nicholas and Havard, Alys},
title = {Effectiveness of smoking cessation pharmacotherapies during pregnancy: A multi‐national population‐based study},
journal = {Addiction},
year = {2026},
doi = {10.1111/add.70290}
}
EUVIMED